STK16

Across TCGA pan-cancer cohorts, STK16 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STK16 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher STK16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STK16 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where STK16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.364	0.951	<.001	63	view →
LUAD	DFS	Quartile	All	0.566	0.827	.017	14	view →
CCRCC	DFS	Median	All	0.676	0.918	.001	9	view →
PDAC	DFS	Quartile	All	0.908	0.387	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

STK16–LSCC (DFS)

Open the LSCC breakdown →